ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 561

Analysing Impairments in Physical Performance as Assessed by the as Performance Index (ASPI) in Patients with Axial Spondyloarthritis (axSpA)

Eerik Ahomaa 1, Uta Kiltz2, Björn Bühring 3, Xenofon Baraliakos 4, Salima van weely 5 and Jürgen Braun 6, 1Rheumazentrum Ruhrgebiet and Ruhr-University Bochum, Bochum, Germany, 2Rheumazentrum Ruhrgebiet/Ruhr University Bochum, Herne, Germany, Herne, Germany, 3Rheumazentrum Ruhrgebiet and Ruhr-University Bochum, Herne, Germany, 4Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, 5Orthopedics, Rehabilitation and Physical Therapy dpt., Leiden University Medical Center, Leiden, Netherlands, 6Rheumazentrum Ruhrgebiet/Ruhr University, Herne, Germany

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: axial spondyloarthritis, performance and physical impairment, physical function

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 10, 2019

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster I: Axial Spondyloarthritis, Clinical Features

Session Type: Poster Session (Sunday)

Session Time: 9:00AM-11:00AM

Background/Purpose: In patients with axial spondyloarthritis (axSpA) physical functioning is frequently impaired. The current gold standard to assess physical functioning is self-reported questionnaires (i.e. BASFI), which, however, are of subjective nature. Therefore, a performance-based test-battery was designed to measure physical functioning more objectively: the ankylosing spondylitis (AS) performance index (ASPI)) [1]. To imitate activities of daily living (ADL), tasks based on BASFI domains, were designed. Although the ASPI had previously been evaluated, a thorough analysis of the deficits of physical functioning and factors which influence the performance of patients with axSpA has not been performed to date.

Methods: Consecutive patients diagnosed with axSpA fulfilling the ASAS classification criteria underwent standardized assessments concentrating on the following variables: patient and disease characteristics, patient-reported outcomes (ASDAS, BASFI, BASMI, ASAS Health Index (ASAS HI), PHQ-9, IPAQ), mSASSSand ASPI (ASPI 1: Bending, 2. Putting on socks, 3. Getting up from the floor) [1]. Performance was measured in seconds as time to complete a task based on published instructions given to the patients. Impairment in physical performance was defined as the inability of patients to perform ≥ 1 ASPI test. Spearman Rho correlation was used to compare self-reported functioning and performed physical functioning. Logistic regression analysis was used to identify factors associated with impaired physical performance.

Results: A total of 200 patients (AS 66%, nr-axSpA 34%) was included: 69% males, 44.3±12.5 years old, mean symptom duration 17.9±12.6 years, BMI 27.2±5.5, mean ASDAS 2.5±1.1, BASFI 4.0±2.7, BASMI 3.5±1.8, ASAS HI 7.0±4.1, PHQ-9 8.8±6.2, and mSASSS(n=157) 10.2±18.8. 133 patients were treated with bDMARDs (66.5%). In total 44 patients (22%) were not able to perform one or more ASPI tests. The mean time for bending was 18.6±9.5 sec (n=179/90%), for putting on socks 12.8±6.4 sec (n=156/78%), and for getting up from floor 6.5±5.0 sec (n=187/94%). A significant correlation was found for all three ASPI-tests with BASFI (0.5-0.7), ASAS HI (0.4-0.6). Self-reported physical activity (IPAQ) correlated weakly with ASPI (all 0.2) and structural damage correlated only with the task putting on socks (r=0.3), whereas the other tests did not correlate. Logistic regression showed an influence of obesity, spinal mobility and global functioning on actual performance but not of disease activity and self-reported physical function (Table 1)

Conclusion: This study confirms a good correlation of the ASPI with standard questionnaires of physical functioning and disease activity. However, the ASPI showed a substantial floor effect, since 22% of patients were unable to perform the tests. This striking finding strongly suggests that more information on the actual performance of patients with axSpA is needed. Our data confirm that self-reported physical activity cannot be used as a substitute for the actual performance of axSpA patients. Moreover, obesity as a potential modifying factor that definitely contributes to limitations in actual performance should also be more carefully addressed in patients with axSpA.


Abstract_ASPI_tab1

Association between clinical characteristics of patients with SpA and physical performance


Disclosure: E. Ahomaa, None; U. Kiltz, AbbVie, 2, 5, 8, ABBVIE, NOVARTIS, CHUGAI, JANSEN, MSD, UCB, 8, ABBVIE, NOVARTIS, LILLY,BIOCAD, GRUNENTHAL,UCB, 5, ABBVIE, NOVARTIS, PFIZER,BIOGEN, 2, Biocad, 2, 5, Biogen, 2, 5, Chugai, 2, 5, 8, Eli Lilly, 2, 5, Eli Lilly and Company, 5, Grünenthal, 2, 5, 8, Janssen, 8, Jasnssen, 2, 5, MSD, 2, 5, 8, Novartis, 2, 5, 8, Pfizer, 2, 5, Roche, 2, 5, 8, UCB, 2, 5, 8; B. Bühring, None; X. Baraliakos, AbbVie, 2, 5, 8, Abbvie, 2, 5, 8, BMS, 2, 5, 8, 9, Bristol-Myers Squibb, 2, 5, 8, Celgene, 2, 5, 8, 9, Chugai, 2, 5, 8, 9, Janssen, 2, 5, 8, 9, Lilly, 2, 8, 9, Merck, 2, 5, 8, MSD, 2, 5, 8, 9, Novartis, 2, 5, 8, 9, Novatis, 2, 5, 8, Pfizer, 2, 5, 8, 9, UCB, 2, 5, 8, 9, UCB Pharma, 2, 5, 8, Werfen, 2, 5, 8; S. van weely, None; J. Braun, Abbott, 2, 5, AbbVie, 2, 5, 6, 8, Amgen, 2, 5, 8, Baxter, 2, 5, 8, Biogen, 2, 8, 9, BMS, 2, 5, 8, Boehringer, 2, 5, 8, Bristol-Myers Squibb, 2, 5, Celgene, 2, 3, 5, 8, Celltrion, 2, 5, 8, Centocor, 2, 5, 8, Chugai, 2, 5, 8, Eli Lilly and Company, 2, 5, 8, Hexal, 2, 5, 8, Janssen, 2, 5, 8, Johnson & Johnson, 2, 5, Medac, 2, 5, 8, MSD, 2, 5, MSD (Schering-Plough), 2, 5, 8, Mundipharma, 2, 5, 8, Mylan, 2, 5, 8, Novartis, 2, 5, 8, Pfizer, 2, 5, Pfizer (Wyeth, Hospira), 2, 5, 8, Roche, 2, 5, 8, Sanofi-Aventis, 2, 5, 8, UCB Pharma, 2, 5, 8.

To cite this abstract in AMA style:

Ahomaa E, Kiltz U, Bühring B, Baraliakos X, van weely S, Braun J. Analysing Impairments in Physical Performance as Assessed by the as Performance Index (ASPI) in Patients with Axial Spondyloarthritis (axSpA) [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/analysing-impairments-in-physical-performance-as-assessed-by-the-as-performance-index-aspi-in-patients-with-axial-spondyloarthritis-axspa/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/analysing-impairments-in-physical-performance-as-assessed-by-the-as-performance-index-aspi-in-patients-with-axial-spondyloarthritis-axspa/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology